ASP Isotopes (NASDAQ:ASPI) Stock Price Down 8.7% – Time to Sell?

ASP Isotopes Inc. (NASDAQ:ASPI) fell 8.7% on Monday . The stock traded as low as $5.30 and last traded at $5.2960. 1,883,470 shares changed hands during trading, a decline of 62% from the average session volume of 4,961,813 shares. The stock had previously closed at $5.80.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Stock Up 4.1%

The firm has a market cap of $634.41 million, a price-to-earnings ratio of -2.34 and a beta of 3.26. The firm has a 50-day moving average of $5.09 and a two-hundred day moving average of $6.03. The company has a current ratio of 12.23, a quick ratio of 12.20 and a debt-to-equity ratio of 0.77.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings results on Friday, April 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.70). ASP Isotopes had a negative return on equity of 161.55% and a negative net margin of 734.14%.The business had revenue of $33.32 million during the quarter, compared to the consensus estimate of $2.03 million.

Insider Buying and Selling

In related news, COO Robert Ainscow sold 25,000 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $4.51, for a total transaction of $112,750.00. Following the completion of the transaction, the chief operating officer directly owned 1,512,817 shares in the company, valued at $6,822,804.67. This represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Duncan Moore sold 11,642 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the completion of the sale, the director owned 1,044,928 shares in the company, valued at $5,444,074.88. This represents a 1.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 90,704 shares of company stock valued at $463,252. 14.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ASP Isotopes by 9.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock worth $148,000 after acquiring an additional 2,709 shares during the period. Rhumbline Advisers increased its position in shares of ASP Isotopes by 20.9% during the second quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock valued at $581,000 after purchasing an additional 13,668 shares during the period. XTX Topco Ltd acquired a new position in shares of ASP Isotopes in the second quarter valued at $178,000. New York State Common Retirement Fund lifted its position in ASP Isotopes by 418.2% in the second quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock worth $126,000 after purchasing an additional 13,800 shares during the period. Finally, Invesco Ltd. boosted its stake in ASP Isotopes by 2,205.0% during the second quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock worth $3,468,000 after buying an additional 450,776 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.